Category Archives: Genetic Engineering

CLAIM

Bill Gates stated that "Were taking things that are genetically modified organisms, and were injecting them into little kids arms; we just shoot them right into the vein"

DETAILS

Lack of context: Bill Gates was speaking about the importance of safety testing in the acceptance of new technologies. He was making a comparison between the safety system for medicines and genetically modified crops.

KEY TAKE AWAY

Genetically modified crops are controversial among the public and farmers. Bill Gates used the example of medical testing as an analogy to make the case for the importance of a safety monitoring system for GM crops. Genetically modified organisms are used in producing certain vaccines, which have been tested in clinical trials to show their safety and efficacy.

REVIEW A video posted on YouTube showed a clip of Bill Gates speaking about injecting children with genetically modified organisms. The video has been viewed more than 15,000 times and shared more than 3,000 times on Facebook, according to the social media analytics tool CrowdTangle.

The clip of Bill Gates was taken from a 2015 event in Brussels as part of a discussion about genetically modified (GM) crops. GM crops are agricultural plants that have been modified using genetic engineering to introduce new traits, such as improved nutritional value or resistance to pests and herbicides. While the scientific consensus is that GM foods are safe to eat, they remain controversial among the public and farmers.

At the event, Gates used the safety testing process for medicines as an analogy to support safety testing for GM crops. Specifically, new medicines go through testing and clinical trials to determine if they are safe and effective. There are numerous stages in the safety testing process, in which results are compared between increasingly larger test groups and untreated people to assess the benefits and risks of a medicine.

The segment below contains Gates quote, shown in context:

The strongest analogy is to medicines. Is there something to worry about with medicines that some of them might have side effects? Do we need safety testing? Were taking things that are genetically modified organisms, and were injecting them into little kids arms; we just shoot them right into the vein. So, yeah, I think maybe we should have a safety system where we do trials and test things out.

Gates used this analogy to compare the potential safety risk of new medical technology to the risk of eating GM crops. Society in general comes to accept new medicines because regulatory agencies ensure that they are safe, based on data from extensive safety testing. In other words, Gates used the example of safety testing of new medicines to argue that safety testing for GM crops is likewise required to boost their acceptance.

Gates statements were part of a wider discussion about the rights of African farmers to choose whether or not to use GM crops. Gates argued that GM crop techniques should not be dismissed entirely, given their potential to solve a range of problems:

The idea though that you would take a technique that promises to solve nutrition problems, solve productivity problems, solve crop disease problems for African farmers, where its absolutely a life-and-death issue for them, and you would say, oh nothing that uses that technique should possibly be used.

Essentially, Gates promoted the idea that having a safety monitoring system in place would help inform decisions by stakeholders on their use, as they do in medicine. However, the manner in which the video was edited made it appear as though Gates was promoting the idea of injecting children with genetically modified organisms, which, as demonstrated above, isnt the case.

Genetically modified organisms are a key part of biologics production, such as vaccine manufacturing. For instance, genetically modified cells are used to produce proteins found in the hepatitis B virus and human papillomaviruses, which are the active ingredients in the respective vaccines that trigger the development of immunity against these viruses. However, it is important to note that these vaccines themselves dont contain genetically modified organisms. These vaccines have been used for many years and data from safety monitoring shows that they are safe and effective(see here and here).

Some COVID-19 vaccines, like the ones produced by AstraZeneca and Johnson & Johnson, also make use of the same technology. These vaccines use a viral vector, where an existing virus called an adenovirus that causes the common cold was genetically modified to carry the genetic sequence coding for the spike protein of SARS-CoV-2. These vaccines were also shown to be safe and effective.

In summary, the video posted on YouTube left out a lot of the context around the comments from Bill Gates. Gates was speaking at an event about genetically modified crops and was arguing for the importance of safety testing.

More:
Bill Gates quoted out of context about injecting kids with genetically modified organisms in discussion on GM crops - Health Feedback

REHOVOT, Israel, March 29, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN),a regenerative and aesthetics medicine company, today announced the appointment of Hugh Evans to its Board of Directors, increasing the board to six independent members.

U.S.-based Mr. Evans brings extensive board, 3D printing technology, and investment experience to CollPlant. He currently serves on the boards of four manufacturing technology companies including Factory Four, ZVerse, 3DM, and is also a Non-Executive Chairman of Culinary Printworks. He was formerly a board member of AquaVenture Holdings, which was acquired by Culligan International.

Mr. Evans served as Senior Vice President of Corporate Development & Digitization at 3D Systems Corporation, a leading 3D printing company, where he led M&A, venture capital investments, joint ventures, and technology licensing. Previously, he served as a portfolio manager at T. Rowe Price Associates in Baltimore, Maryland for over 20 years.

"Hugh brings significant insights and experience that will be invaluable to CollPlant as we continue to execute our strategic vision. His achievements as a senior executive and board member, complemented by his notable expertise in the 3D printing industry will undoubtedly serve us well as we continue to grow, " said Yehiel Tal, CollPlant Chief Executive Officer. "Hugh is an excellent addition to our board of directors and will play an integral role in our mission to help people live longer and better through our innovative collagen technology."

"I'm thrilled to join CollPlant's board at a pivotal time in the Company's mission to revolutionize the fieldsof regenerative and aesthetic medicine via its rhCollagen technology platform," said Mr. Evans. "I look forward to contributing from my experience in additive manufacturing to support CollPlant in pioneering novel solutions for patients around the world."

CollPlant's Chairman, Dr. Roger J. Pomerantz commented, "Hugh has a deep understanding and appreciation of CollPlant's technology and how it can be transformative in advancing the 3D bioprinting field. We are very pleased to welcome him to the board and look forward to his guidance and support."

About CollPlant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. CollPlant recently entered a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.

For more information, visithttp://www.collplant.com.

Safe Harbor Statements

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the impact of the COVID-19 pandemic; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk and products for medical aesthetics; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk and medical aesthetics products including but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact at CollPlant:Eran RotemDeputy CEO & Chief Financial OfficerTel: + 972-73-2325600/631Email:Eran@collplant.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/collplant-appoints-additive-manufacturing-executive-hugh-evans-to-its-board-of-directors-301257385.html

SOURCE CollPlant

Read more from the original source:
CollPlant Appoints Additive Manufacturing Executive, Hugh Evans to Its Board of Directors - BioSpace

A new research report published by Fior Markets with the titleGenome Editing Market by Technology(ZFN, TALENs/MegaTALs, CRISPR/Cas9, Others), Delivery Method (In-Vivo, Ex-Vivo), Application (Cell Line Engineering, Plant Genetic Engineering, Animal Genetic Engineering, Other Applications), End-Use (Contract Research Organizations, Academic & Government Research Institutes, Biotechnology & Pharmaceutical Companies), Service (In-house, Contract), Region, Global Industry Analysis, Market Size, Share, Growth, Trends, andForecast 2021 to 2028

Theglobal genome editing marketis expected to grow from USD 5.37 billion in 2020 to USD 17.36 billion by 2028, at a CAGR of 15.8% during the forecast period 2021-2028. The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period 2021-2028. This growth is owing to factors like advancing medical science and rising disposable income. On the other hand, the North America region accounted for the major market share of 48.2% in the year 2020 and is anticipated to grow throughout the projected period. The large share of this segment is attributed to key factors such as R&D activities in gene therapy, increasing cases of cancer & other diseases, increasing funding & research grants, and rising usage of GM (genetically modified) crops in the region.

NOTE:Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post the COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/419241/request-sample

Key players in the global genome editing market are Thermo Fisher Scientific, Horizon Discovery Limited, GenScript, Eurofins Scientific, Editas Medicine, CRISPR Therapeutics, Oxford Genetics, Synthego, Vigene Biosciences, Integrated DNA Technologies, OriGene Technologies, Transposagen Biopharmaceuticals, Agilent Technologies, Genecopoeia, and Precision Biosciences, among others. Key companies are mainly focusing on developing new products, forming partnerships, and joint ventures to gain significant market share in the global genome editing market.

The technology segment consists of ZFN, TALENs/MegaTALs, CRISPR/Cas9, and others. CRISPR/Cas9 segment dominated the market and held the largest market share of 32.8% in the year 2020. This is primarily due to CRISPRs better ease of use as compared to TALEN & ZFN, and patient-specific treatment characteristics for illnesses like cystic fibrosis. Based on delivery method, the global market has been divided into in-vivo and ex-vivo. The in-vivo segment is expected to grow at the highest CAGR of 17.6% over the forecast period due to a large number of diseases which can be treated via in-vivo. The application segment includes cell line engineering, plant genetic engineering, animal genetic engineering, and other applications. The cell line engineering dominated the market and held the largest market share of 34.1% in the year 2020. Some of the vital factors that drive market growth in this segment are rising government as well as private funding, increasing global awareness, and expanding industry attention on stem cell research. Based on end-use, the genome editing market has been segmented into contract research organizations, academic & government research institutes, and biotechnology & pharmaceutical companies. The academic & government research institutes segment is set to register the highest growth of 16.9% due to the increasing adoption of genome editing technology in university-grade experiments & projects. Based on service, the market has been divided into in-house and contract. The in-house segment dominated the market and held the largest market share of 60.9% in the year 2020. Large companies like Sigma Aldrich Corporation and Thermo Fisher engineer cell lines in-house due to the availability of financial resources, technology, and facilities.

ACCESS FULL REPORT:https://www.fiormarkets.com/report/genome-editing-market-by-technology-zfn-talens-megatals-crispr-cas9-others-419241.html

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.

Contact UsMark StonePhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

Here is the original post:
Global Genome Editing Market Projected To Grow At A CAGR Of 15.8 % By 2028 - PharmiWeb.com

DUBLIN, March 4, 2021 /PRNewswire/ -- The "Biohacking Market Share, Size, Trends, Industry Analysis Report, By Type; By Product; By Application; By End Use; By Regions; Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global biohacking market size is expected to reach USD 52,779.36 million by 2027, according to the study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.

Biohacking are biological experiments conducted in a small lab and are done by either individual or a small community. That is why biohacking is also called Do-It-Yourself (DIY). The biological experiments performed in garage labs could be genetic engineering, 3-D printing using light-sensitive bacteria. Furthermore, biohackers are in process as well as have developed various products to explore the human body and mind such as smart drugs, microchips, brain sensors, magnetic fingerprints, RFID implants, bacterial and yeast strains, smart blood pressure monitor and health tracker.

For functional or aesthetic changes, biohackers have implemented technology to their own bodies. For instance, Artist Neil Harbission has exceptional color blindness due to which he used to see every object in grey color only. Later, he and his team had developed a software that transposes colors into vibration using a head-mounted camera extension.

The growing awareness about biohacking and the increasing prevalence of chronic diseases across the globe are the factors driving the growth of the market. Currently, the COVID-19 crisis has led to a rise in market growth for the pharma industries, and several R&D activities have been conducted by the companies to develop a suitable drug t as well as control the crisis. Therefore, increasing research & development activities by the company is the factor anticipated to fuel the market.

However, the lack of cybersecurity practices and expertise, severe regulations that govern the genetic engineering experiments are anticipated to restrain the market growth during the projection period. On the other hand, lack of funding in research & development by the government yet remains another factor that limits the growth of the market. Furthermore, Salvia Bioelectronics, a Dutch startup company, is developing neurostimulation implantable device to stop chronic migraines. At its early stage of R&D, the company has successfully raised a fund of 1.8 million euros, in 2019. Additionally, smaller U.S. startups like CVRx has raised USD 340.6 million while Setpoint has raised USD 84.3 million. CVRx makes implant for heart failure treatment while Setpoint develops neuro devices for the treatment of arthritis and Crohn's disease. This shows a great opportunity for biohackers.

Market participants such as Thync Global Inc., Apple, HVMN, Inc., Synbiota, Grindhouse Wetware, MoodMetric, THE ODIN, and Fitbit, Inc. are some of the key players operating in the market. The companies operating in the market are involved in the development of the product, strategic initiative, and regional expansion. For instance, Tim Cannon (co-founder of Grindhouse wetware) had implanted a circadia device into his arm. This was the very first event of body implantation. The Circadia device is capable of monitoring body temperature.

Key Topics Covered:

1. Introduction1.1. Report Description1.1.1. Objectives of the Study1.1.2. Market Scope1.1.3. Assumptions1.2. Stakeholders

2. Executive Summary2.1. Market Highlights

3. Research Methodology3.1. Overview3.1.1. Data Mining3.2. Data Sources3.2.1. Primary Sources3.2.2. Secondary Sources

4. Biohacking Market Insights4.1. Biohacking - Industry snapshot4.2. Biohacking Market Dynamics4.2.1. Drivers and Opportunities4.2.1.1. Technological advancements4.2.1.2. Government backed funding4.2.2. Restraints and Challenges4.2.2.1. Bioethics4.3. Porter's Five Forces Analysis4.3.1. Bargaining Power of Suppliers (Moderate)4.3.2. Threats of New Entrants: (Low)4.3.3. Bargaining Power of Buyers (Moderate)4.3.4. Threat of Substitute (Moderate)4.3.5. Rivalry among existing firms (High)4.4. PESTLE Analysis4.5. Biohacking Market Industry trends

5. Biohacking Market Assessment by Type5.1. Key Findings5.2. Introduction5.2.1. Global Biohacking Market, By Type, 2016-2027 (USD Million)5.3. Inside5.3.1. Global Biohacking Market, by Inside, by Region, 2016- 2027 (USD Million)5.4. Outside5.4.1. Global Biohacking Market, by Outside, by Region, 2016- 2027 (USD Million)

6. Global Biohacking Market, by Product6.1. Key Findings6.2. Introduction6.2.1. Global Biohacking Market, By Product, 2016-2027 (USD Million)6.3. Smart Drugs6.3.1. Global Biohacking Market, by Smart Drugs, By Region, 2016- 2027 (USD Million)6.4. Sensors6.4.1. Global Biohacking Market, by Sensors, by Region, 2016- 2027 (USD Million)6.5. Strains6.5.1. Global Biohacking Market, by Strains, by Region, 2016- 2027 (USD Million)6.6. Others6.6.1. Global Biohacking Market, by Others, by Region, 2016- 2027 (USD Million)

7. Global Biohacking Market, by Application7.1. Key Findings7.2. Introduction7.2.1. Global Biohacking Market, By Application, 2016-2027 (USD Million)7.3. Synthetic Biology7.3.1. Global Biohacking Market, by Synthetic Biology, By Region, 2016- 2027 (USD Million)7.4. Genetic Engineering7.4.1. Global Biohacking Market, by Genetic Engineering, by Region, 2016- 2027 (USD Million)7.5. Forensic Science7.5.1. Global Biohacking Market, by Forensic Science, by Region, 2016- 2027 (USD Million)7.6. Diagnosis & Treatment7.6.1. Global Biohacking Market, by Diagnosis & Treatment, by Region, 2016- 2027 (USD Million)7.7. Drug Testing7.7.1. Global Biohacking Market, by Drug Testing, by Region, 2016- 2027 (USD Million)

8. Biohacking Market Assessment by End Use8.1. Key Findings8.2. Introduction8.2.1. Global Biohacking Market, By End Use, 2016-2027 (USD Million)8.3. Pharmaceutical & Biotechnology Companies8.3.1. Global Biohacking Market, by Pharmaceutical & Biotechnology Companies, by Region, 2016- 2027 (USD Million)8.4. Forensic Laboratories8.4.1. Global Biohacking Market, by Forensic Laboratories, by Region, 2016- 2027 (USD Million)8.5. Others8.5.1. Global Biohacking Market, by Others, by Region, 2016- 2027 (USD Million)

9. Biohacking Market Assessment by Geography9.1. Key findings9.2. Introduction9.3. Biohacking Market - North America9.4. Biohacking Market - Europe9.5. Biohacking Market - Asia-Pacific9.6. Biohacking Market - Middle East & Africa9.7. Biohacking Market - Latin America

10. Competitive Landscape10.1. Expansion and Acquisition Analysis10.1.1. Expansion Analysis10.1.2. Acquisition Analysis10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles11.1. Thync Global Inc.11.1.1. Company Overview11.1.2. Financial Performance11.1.3. Product/Services Benchmarking11.1.4. Recent Developments11.1.5. Apple11.1.6. Company Overview11.1.7. Financial Performance11.1.8. Product/Services Benchmarking11.1.9. Recent Developments11.2. HVMN11.2.1. Company Overview11.2.2. Financial Performance11.2.3. Product/Services Benchmarking11.2.4. Recent Developments11.3. Synbiota11.3.1. Company Overview11.3.2. Financial Performance11.3.3. Product/Services Benchmarking11.3.4. Recent Developments11.4. Grindhouse Wetware11.4.1. Company Overview11.4.2. Financial Performance11.4.3. Product/Services Benchmarking11.4.4. Recent Developments11.5. MoodMetric11.5.1. Company Overview11.5.2. Financial Performance11.5.3. Product/Services Benchmarking11.5.4. Recent Developments11.6. THE ODIN11.6.1. Company Overview11.6.2. Financial Performance11.6.3. Product/Services Benchmarking11.6.4. Recent Developments11.7. Fitbit, Inc.11.7.1. Company Overview11.7.2. Financial Performance11.7.3. Product/Services Benchmarking11.7.4. Recent Developments

For more information about this report visit https://www.researchandmarkets.com/r/qexfba

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Go here to see the original:
Insights on the Biohacking Global Market to 2027 - by Type, Product, Application, End-use and Regions - PRNewswire

According to the report, the global synthetic biology market was valued atUS$ 4.96 Bnin 2020and is projected to expand at a CAGR of26.3%from2021to2027

Latest added Synthetic Biology Market research study by MarketDigits offers detailed product outlook and elaborates market review till 2026. The market Study is segmented by key regions that is accelerating the marketization. At present, the market is sharping its presence and some of the key players in the study areThermo Fischer Scientific, GenScript, Integrated DNA technologies, Eurofins Scientific, Origene technologies, Scientific genomics. The study is a perfect mix of qualitative and quantitative Market data collected and validated majorly through primary data and secondary sources.

Request for Free Sample Copy of This Report @https://marketdigits.com/synthetic-biology-market/sample

This report studies the Synthetic Biology Market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the Synthetic Biology Market by companies, region, type and end-use industry.

Scroll down 100s of data Tables, charts and graphs spread through Pages and in-depth Table of Content on Synthetic Biology Market, By Products (Synthetic DNA, Synthetic Oligos, Synthetic Genes, Software Tools, Chassis Organisms, Synthetic Clones, Synthetic Cells), Technology (Nucleotide Synthesis And Sequencing, Bioinformatics, Microfluidics, Genetic Engineering), Application (Medical Applications, Industrial Applications, Environmental Applications) and Geography Global Forecast to 2026. Early buyers will get 10% customization on study.

To Avail deep insights of Synthetic Biology Market Size, competition landscape is provided i.e. Revenue Analysis (M $US) by Company (2018-2020), Segment Revenue Market Share (%) by Players (2018-2020) and further a qualitative analysis is made towards market concentration rate, product/service differences, new entrants and the technological trends in future.

Unlock new opportunities in Synthetic Biology Market; the latest release fromMarketDigitshighlights the key market trends significant to the growth prospects, Let us know if any specific players or list of players needs to consider to gain better insights.

Grab Complete Details with TOC For Free @https://marketdigits.com/synthetic-biology-market/toc

Synthetic Biology Market: Overview

Increase in Investments by Government and Private Organizations into Synthetic Biology Market

Rise in Prevalence of Various Diseases and Technology Advancements: A Key Driver

Biosafety, Biosecurity, and Ethical Risk Related to Synthetic Biology to Hamper Synthetic Biology Market

Global Synthetic Biology Market: Key Developments

Key players in the global synthetic biology market are engaged in regulatory approvals, advanced product development, launch of new products, increase in investments and funds, and acquisition & collaborative agreements with other companies. These strategies of key players are likely to fuel growth of the global synthetic biology market. A few expansion strategies adopted by players operating in the synthetic biology market are:

North America to Account for Major Share of Global Synthetic Biology Market

Global Synthetic Biology Market: Competitive Landscape

Analysis and discussion of important industry trends, market size, market share estimates are also covered in this global Synthetic Biology market report. The usefulness of SWOT analysis & Porter's Five Forces analysis in generating market research report makes it preferable by the businesses and hence also used while preparing this Synthetic Biology report. Synthetic Biology market report consists of market analysis by regions, especially North America, China, Europe, Southeast Asia, Japan, and India, focusing top manufacturers in global market, with production, price, revenue, and market share for each manufacturer. Being the most suitable example of the key market attributes, this Synthetic Biology report has been prepared by keeping in mind every market related aspect.

Which market aspects are illuminated in the report?

Executive Summary: It covers a summary of the most vital studies, the Global Synthetic Biology market increasing rate, modest circumstances, market trends, drivers and problems as well as macroscopic pointers.

Study Analysis: Covers major companies, vital market segments, the scope of the products offered in the Global Synthetic Biology market, the years measured and the study points.

Company Profile:Each Firm well-defined in this segment is screened based on a products, value, SWOT analysis, their ability and other significant features.

Manufacture by region:This Global Synthetic Biology report offers data on imports and exports, sales, production and key companies in all studied regional markets.

Table of Contents:

1 Scope of the Report

2 Executive Summary

3 Global Synthetic Biology by Players

4 Synthetic Biology by Regions

5 Americas

6 APAC

7 Europe

8 Middle East & Africa

9 Market Drivers, Challenges and Trends

10 Global Synthetic Biology Market Forecast

11 Key Players Analysis

12 Research Findings and Conclusion

13 List of Tables

14 List of Figures

Any Questions? Inquire Here Before Buying @https://marketdigits.com/synthetic-biology-market/analyst

About MarketDigits :

MarketDigitsis one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We atMarketDigitsbelieve that market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.

We offer services that are most relevant and beneficial to the users, which help businesses to sustain in this competitive market. Our detailed and in-depth analysis of the markets catering to strategic, tactical, and operational data analysis & reporting needs of various industries utilize advanced technology so that our clients get better insights into the markets and identify lucrative opportunities and areas of incremental revenues.

Contact Us :

MarketDigits

Phone : +91-9822485644

Email : sales@marketdigits.com

Read the original here:
Synthetic Biology Market 2021 Latest Research, Business Overview, Industry Analysis, Driver, Trends and Key Value | Integrated DNA technologies, Eurof...

MENLO PARK, Calif. and BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Andrew Sinclair, Ph.D., to its board of directors. Dr. Sinclair will replace Erez Chimovits, who will step down from the Board of Directors.

Abingworth was a significant investor in our recent successful $152 million financing and we are extremely pleased to welcome Andrew, a highly-respected healthcare investor, to our Board of Directors, said Chen Schor, President and Chief Executive Officer of Adicet Bio, Inc. Andrews significant life science experience amassed throughout his career, both from the financial and scientific perspective, will be tremendously valuable to Adicet as we continue to advance ADI-001 into the clinic and expand our pipeline of off-the-shelf gamma delta T cell product candidates. In addition, we would like to thank Erez for his five years of service and significant contributions to Adicet which have played an important role in advancing our strategic priorities.

I am excited to join Adicet Bios Board of Directors, said Andrew Sinclair. Adicets allogeneic gamma delta T cell approach has a number of potential advantages over other cell therapy platforms and I look forward to working with my fellow board members and company management to advance Adicets corporate goals in the years ahead.

Dr. Sinclair is currently a partner and portfolio manager at Abingworth LLP, a life sciences investment group. He has been at Abingworth since 2008 where he has served in various positions focusing on investments in public and private biotech and pharmaceutical companies. Dr. Sinclair currently serves on the boards of directors of Soleno Therapeutics, Inc., Sierra Oncology and Verona Pharma plc. Prior to joining Abingworth, he was senior equity analyst, director, at HSBC Global Markets, where he was responsible for investment research in the mid-cap pharmaceutical sector. Previously, Andrew held biotechnology analyst positions at Credit Suisse and SG Cowen. Dr. Sinclair received his B.Sc. in Microbiology from King's College London and his Ph.D. in Chemistry and Genetic Engineering at the BBSRC Institute of Plant Science, Norwich. Andrew qualified as a chartered accountant with KPMG.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

About Abingworth

Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in 172 life science companies, leading to 44 M&As and 69 IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston.

Forward-Looking Statements

This press release contains forward-looking statements of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business and operations of Adicet including, but not limited to preclinical and clinical development of Adicets product candidates, including future plans or expectations for ADI-001 and potential therapeutic effects of ADI-001, the timing and outcome of discussions with FDA and other regulatory agencies, expectations regarding the design, implementation, timing, and success of its future clinical studies of ADI-001, and our growth as a company and the anticipated contribution of the members of our board of directors to our operations and progress. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on managements current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, Adicets ability to execute on its strategy; that positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; the expected impact and contribution of our board of directors and executives to our business as well as those risks and uncertainties set forth in the companys most recent quarterly report on Form 10-Q and subsequent filings with the Securities and Exchange Commission. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicets actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in Adicets most recent annual report on Form 10-K and our periodic reports on Form 10-Q and Form 8-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Adicets other filings with the SEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.

Adicet Bio, Inc.Investor and Media Contacts

Anne Bowdidgeabowdidge@adicetbio.com

Janhavi MohiteStern Investor Relations, Inc.212-362-1200janhavi.mohite@sternir.com

View post:
Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors - GlobeNewswire

The United Nations Food Systems Summit, scheduled for September 2021, is facing the threat of a massive boycott, according to a report in the Guardian, with accusations that the summit is biased in favour of corporate, high-tech intensive agriculture.

Anger arose after the summits concept paper was revealed, reportedly highlighting the importance of precision agriculture, data collection and genetic engineering in addressing the food crisis, but making no reference to ecological farming or civil society involvement.

The UN special rapporteur on the right to food, Michael Fakhri, wrote that the summit appeared heavily skewed in favour of one type of approach to food systems, namely market-based solutions.

The business sector has been part of the problem of food systems, he stated, and has not been held accountable.

The summit was initially welcomed for recognising that farming had largely been ignored in climate talks. Its brief was to find ways to reduce hunger and improve global food systems, according to the Guardian, in the face of worsening climate and biodiversity crises.

However, it was the UN secretary generals appointment of Agnes Kalibata to head the event that sparked the first controversy.

The former Rwandan agriculture minister is president of the Gates-funded Alliance for a Green Revolution in Africa (Agra), which was set up in 2006 to open the continent up to genetically modified crops, high-yield commercial seed varieties and intensive farming, the Guardian reported.

In a statement to the newspaper, Kalibata defended her appointment, as well as the goals of the summit. I know those among the worlds most vulnerable and I am determined that this summit will not let them down, she said. We have designed the summit to ensure every voice is heard. We do not expect everyone to agree on everything from the outset.

The Civil Society and Indigenous Peoples Mechanism, a group of over 500 civil society groups with more than 300m members, revealed that it would boycott the event and set up an alternative meeting.

Timothy Wise, senior adviser at the Institute for Agriculture and Trade Policy in the US, lamented the missed opportunity to hear from successful farmer-led groups.

A growing number of farmers, scientists and development experts now advocate a shift from high-input chemical-intensive agriculture to low-input ecological farming, he noted. They are supported by an array of new research documenting both the risks of continuing to follow our current practices and the potential benefits of a transition to more sustainable farming.

Read more from the original source:
UN Summit faces boycott threat - Fruitnet

Genetically engineering female grey squirrels to make them infertile could be a highly effective way to control their numbers and make way for declining red squirrel populations, a study has found.

Conservationists have long sought to reduce numbers of invasive grey squirrels, which were imported as curiosities from the US in the 1890s and started to wreak havoc on the UKs native red squirrels.

Grey squirrels carry a disease a parapoxvirus -which does not appear to affect their health but often kills red squirrels. Greys are more likely to eat green acorns, so will decimate the food source before they ripen and the reds can make use of them.

Green Shoots: i's Guide to Helping the Planet in your Everyday Life

Scientists are working on a new technique to alter their genetic makeup and, using computer modelling, they have demonstrated its potential to significantly reduce grey squirrel numbers.

The next step is to perfect the gene altering technique, which is well advanced in insects but still needs quite a lot of development before it could be used in rodents.

It would also require regulatory approval and probably public acceptance before it was used in the real world, although the Government is actively considering relaxing restrictions on gene editing.

The technique involves tweaking a key female fertility gene in a group of grey squirrels and releasing them into the wild.

Nicky Faber, who did the research at Edinburgh University and is now a PhD candidate at WageningenUniversity and Research in the Netherlands, said: The modelling shows that the technique is very effective at reducing the population size. It will spread through the population so after a certain number of generations, all grey squirrels will have the engineered gene and this will cause a lot of females to be infertile.

The programme would probably require an annual release of newly engineered grey squirrels, with numbers depending on factors such as the local population and the effectiveness of the technique in real life, she said.

The technique also has broader applications.

Ms Faber said: This technology is exciting because it could help solve some other big challenges: to control or immunize malaria-transmitting mosquitoes, to immunize vulnerable species threatened by a pathogen, or to control agricultural pests.

It is more humane than current pest control measures such as shooting, trapping, and poisoning. Also, it is more sustainable as it is species-specific, so it has no negative effects to other species.

A lot of research still needs to be done to make the technology practically applicable, but once it is, the technology could be a great tool in our conservation toolbox, she said.

Professor Luke Alphey, of the Pirbright Institute in London, who was not involved in the research said: Regulatory approval and public acceptance would obviously be essential before any actual use of such technology that is a long way off, but this paper indicates that gene drives could be a valuable tool in the conservation toolbox.

Originally posted here:
Genetically altering grey squirrel fertility could help the native red say scientists - iNews

PHILADELPHIA, March 3, 2021 /PRNewswire/ --Century Therapeutics, a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the closing of a $160 million Series C financing. The financing was led by Casdin Capital and brought together a syndicate of new investors including Fidelity Management & Research LLC, the Federated Hermes Kauffmann Funds, RA Capital, Logos Capital, OrbiMed, Marshall Wace, Qatar Investment Authority, Avidity Partners, and Octagon Capital.Founding investorsVersant Ventures and Leaps by Bayer also participated. Eli Casdin, Founder and Chief Investment Officer of Casdin Capital will be joining the Century Therapeutics Board of Directors.

"We are fortunate to be surrounded by such a top-tier group of investors, whose support will enable the acceleration of Century's technology platform into the clinic," said Lalo Flores, Chief Executive Officer, Century Therapeutics. "With this new investor partnership, we are well-positioned to capitalize on the tremendous potential of our integrated iPSC, cell engineering and manufacturing capabilities to develop safer, more effective and more affordable next generation allogeneic cancer therapies."

Funds raised will help advance Century's rich pre-clinical pipeline, which includes multiple iPSC-derived CAR-iT and CAR-iNK cell products. These products are designed to resist host rejection, enhance cell persistence, and allow repeat dosing to provide durable responses in all patients. The team anticipates beginning clinical testing of its first products in 2022, as well as generating multiple INDs annually in the coming years.

"It's a remarkable and transformative time in the field, with the ability to engineer cells for therapeutic impact now a commercial reality. At the same time, iPSC technology has matured and is now leading the transition from bespoke autologous products to off-the-shelf allogeneic ones." said Eli Casdin CIO of Casdin Capital. "We could not be more excited to partner with the expert team at Century Therapeutics and do our part to help them leverage and accelerate their deep technical expertise in cellular reprogramming, differentiation, genetic engineering and manufacturing to deliver on this next phase of cellular therapy."

About Century Therapeutics

Century Therapeutics is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care. For more information, please visit http://www.centurytx.com.

SOURCE Century Therapeutics

Home

See the rest here:
Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline - PRNewswire

DUBLIN, March 4, 2021 /PRNewswire/ -- The "Pharma 4.0" report has been added to ResearchAndMarkets.com's offering.

This report provides detailed exposure to the Pharma 4.0 market. This report also highlights the current and future market potential of Pharma 4.0 along with a detailed analysis of the competitive environment, regulatory scenario, technological advancement, and drivers, restraints, opportunities and trends in market growth.

This study's goals are to determine the current market scenario for Pharma 4.0 and to assess the market's growth potential during the forecast period. The research explores market dynamics such as drivers, restraints, opportunities, and trends that will have an impact on the growth of the market for Pharma 4.0. The study offers a comprehensive analysis of the current market for Pharma 4.0 and the future direction of the market.

Reasons for Doing This Study

Technological advances over the last three centuries have helped make people's lives easier and richer. Technology has continually advanced to a higher level from one era to the next, starting with the Industrial Revolution. Now, we are seeing the start of the Fourth Industrial Revolution, also known as Industry 4.0.

The First Industrial Revolution followed the proto-industrialization period. This industrial revolution started in the eighteenth century with the advent of the steam engine when steam began powering everything from agriculture machinery to textile manufacturing. This industrial revolution is also called 'The Age of Mechanical Production.' Agrarian societies gave way to urbanization with steam power.

The Second Industrial Revolution began toward the end of the nineteenth century with massive technological advancements that led to the emergence of new sources of energy such as electricity, gas and oil. Other important advances in The Second Industrial Revolution included developments in steel production, chemicals and methods of communication such as the telegraph and the telephone. The Second Industrial Revolution is considered the most important one to this day because of the inventions of the automobile and the plane at the beginning of the twentieth century.

The Third Industrial Revolution was brought forth through the rise of electronics, telecommunications and of course computers. Through these new technologies, the third industrial revolution opened the doors to space exploration, Internet communications and biotechnology.

The Fourth Industrial Revolution can be described as the blurring of boundaries between the physical, digital and biological worlds. It is a fusion of advances in artificial intelligence (AI), robotics, the Internet of Things (IoT), 3D printing, genetic engineering, quantum computing, and other technologies. Industry 4.0 is emerging within subsets of various vertical industries, with one of the first being the pharmaceutical industry.

Report Includes:

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Pharma 4.0: Technology Background

Chapter 3 Medical Device Regulations

Chapter 4 Pharma 4.0: Market Dynamics

Chapter 5 Impact of COVID-19 Pandemic

Chapter 6 Key Technologies in Pharma 4.0

Chapter 7 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/hbun9d

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

View original post here:
Overview of the Global Pharma 4.0 market with an Emphasis on Digital Manufacturing of Pharmaceutical Products, 2021 Report - PRNewswire